This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wei, Q. Articles by Guha, A. Search for Related Content PubMed PubMed Citation Articles by Wei, Q. Articles by Guha, A.

High-Grade Glioma Formation Results from Postnatal Pten Loss or Mutant Epidermal Growth Factor Receptor Expression in a Transgenic Mouse Glioma Model

¹ Arthur & Sonia Labatt Brain Tumour Research Centre and ² Mouse Imaging Centre, The Hospital for Sick Children; ³ Division of Neuropathology and Neurosurgery, University Health Network, Toronto, Ontario, Canada; ⁴ Department of Neurology, Washington University of Medicine, St. Louis, Missouri; and ⁵ The Wistar Institute, Philadelphia, Pennsylvania

Requests for reprints: Abhijit Guha, Fellow of the Royal College of Surgeons of Canada, 4W-446 Toronto Western Hospital, 399 Bathurst Street, Toronto, Ontario, Canada M5T 2S8. Phone: 416-603-5740; Fax: 416-603-5298; E-mail: Abhijit.Guha{at}uhn.on.ca.

High-grade gliomas are devastating brain tumors associated with a mean survival of <50 weeks. Two of the most common genetic changes observed in these tumors are overexpression/mutation of the epidermal growth factor receptor (EGFR) vIII and loss of PTEN/MMAC1 expression. To determine whether somatically acquired EGFRvIII expression or Pten loss accelerates high-grade glioma development, we used a previously characterized RasB8 glioma-prone mouse strain, in which these specific genetic changes were focally introduced at 4 weeks of age. We show that both postnatal EGFRvIII expression and Pten inactivation in RasB8 mice potentiate high-grade glioma development. Moreover, we observe a concordant loss of Pten and EGFR overexpression in nearly all high-grade gliomas induced by either EGFRvIII introduction or Pten inactivation. This novel preclinical model of high-grade glioma will be useful in evaluating brain tumor therapies targeted to the pathways specifically dysregulated by EGFR expression or Pten loss. (Cancer Res 2006; 66(15): 7429-37)

This article has been cited by other articles:

				C.-H. Kwon, D. Zhao, J. Chen, S. Alcantara, Y. Li, D. K. Burns, R. P. Mason, E. Y.-H. P. Lee, H. Wu, and L. F. Parada Pten Haploinsufficiency Accelerates Formation of High-Grade Astrocytomas Cancer Res., May 1, 2008; 68(9): 3286 - 3294. [Abstract] [Full Text] [PDF]

				S. Ivkovic, P. Canoll, and J. E. Goldman Constitutive EGFR Signaling in Oligodendrocyte Progenitors Leads to Diffuse Hyperplasia in Postnatal White Matter J. Neurosci., January 23, 2008; 28(4): 914 - 922. [Abstract] [Full Text] [PDF]

				M. J. Jarzynka, B. Hu, K.-M. Hui, I. Bar-Joseph, W. Gu, T. Hirose, L. B. Haney, K. S. Ravichandran, R. Nishikawa, and S.-Y. Cheng ELMO1 and Dock180, a Bipartite Rac1 Guanine Nucleotide Exchange Factor, Promote Human Glioma Cell Invasion Cancer Res., August 1, 2007; 67(15): 7203 - 7211. [Abstract] [Full Text] [PDF]

				S. M. Dunlap, J. Celestino, H. Wang, R. Jiang, E. C. Holland, G. N. Fuller, and W. Zhang Insulin-like growth factor binding protein 2 promotes glioma development and progression PNAS, July 10, 2007; 104(28): 11736 - 11741. [Abstract] [Full Text] [PDF]